About this Research Topic
The causes of inflammatory diseases are complex and not fully understood, resulting in knowledge gaps that require interdisciplinary research. One of the main reasons for this is the complex nature of the immune system and its interaction with other physiological systems, such as the nervous, endocrine, and metabolic systems. Other challenges include the heterogeneity of inflammatory disorders and the interplay between genetic and environmental factors in the development and progression of inflammatory disorders. In particular, there is a need for new developments in understanding the molecular and cellular mechanisms underlying lung and metabolism inflammation.
Recent advances in genetic research and -omics technologies have led to the discovery of new genes and pathways involved in inflammatory diseases of the lung and metabolism. These discoveries have enabled researchers to identify novel biomarkers and therapeutic targets for lung and metabolic inflammation, as well as to develop more personalized and precise therapies. Hence, there is a need for new anti-inflammatory drugs that are safe, effective, and have fewer side effects, and targeting specific molecules and cells, as well as modulating the microbiome, are promising approaches for developing such drugs.
Led by Dr. Sheikh Rayees with support from Dr. Sheikh Tasduq Abdullah, Dr. Mumtaz Anwar, Dr. Javeed Bhat, and Dr. Mona Al-Ahmad, this Research Topic will address the identification of new drug targets based on recent advances in the biology of the inflammation of the lung and metabolism and new information on the molecular and cellular mechanisms underlying these inflammatory illnesses. Researchers are welcome to submit articles that address knowledge gaps in the field of these inflammatory diseases. We also encourage submissions that feature innovative therapeutic interventions for inflammatory diseases of lung and metabolism, based on newer drug targets. Overall, this Research Topic aims to highlight cutting-edge research that can advance our understanding and treatment of these inflammatory diseases.
Recent advances in genetic research and -omics technologies have led to the discovery of new genes and pathways involved in inflammatory diseases of the lung and metabolism. These discoveries have enabled researchers to identify novel biomarkers and therapeutic targets for lung and metabolic inflammation, as well as to develop more personalized and precise therapies. Hence, there is a need for new anti-inflammatory drugs that are safe, effective, and have fewer side effects, and targeting specific molecules and cells, as well as modulating the microbiome, are promising approaches for developing such drugs.
Led by Dr. Sheikh Rayees with support from Dr. Sheikh Tasduq Abdullah, Dr. Mumtaz Anwar, Dr. Javeed Bhat, and Dr. Mona Al-Ahmad, this Research Topic will address the identification of new drug targets based on recent advances in the biology of the inflammation of the lung and metabolism and new information on the molecular and cellular mechanisms underlying these inflammatory illnesses. Researchers are welcome to submit articles that address knowledge gaps in the field of these inflammatory diseases. We also encourage submissions that feature innovative therapeutic interventions for inflammatory diseases of lung and metabolism, based on newer drug targets. Overall, this Research Topic aims to highlight cutting-edge research that can advance our understanding and treatment of these inflammatory diseases.
Keywords: Inflammation, Drug Discovery, Cell signalling, microbiome, Novel drug targets, Metabolism
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
